Filter Results:
(260)
Show Results For
- All HBS Web
(260)
- News (29)
- Research (197)
- Multimedia (2)
- Faculty Publications (101)
Show Results For
- All HBS Web
(260)
- News (29)
- Research (197)
- Multimedia (2)
- Faculty Publications (101)
- December 2010
- Teaching Note
Organization and Strategy at Millennium (TN) (A) & (B)
By: Julie M. Wulf
Teaching Note for 710-415 and 710-418. View Details
- Fast Answer
Patent search: Cortellis
How can I begin a patent search in Cortellis and can I search by therapeutic areas, e.g.? Cortellis for Competitive Intelligence combines a collection of pharmaceutical industry data and life science related... View Details
Charles H. Revson
Known for his autocratic and direct management style, Revson built Revlon into the second largest cosmetics company in the U.S. Revson's unique talent of grasping the female psyche, bolstered by his fiercely competitive nature, allowed... View Details
Keywords: Personal Care & Home Products
- Fast Answer
Pharmaceuticals: Pipeline
where can I find pharmaceuticals pipeline data? In addition to the following sources, we suggest that you also check company’s website for latest pipeline info. You may begin with: Bloomberg - It is Drug Profiles allows to screen by... View Details
- December 2014 (Revised October 2017)
- Case
Social Business at Novartis: Arogya Parivar
By: Michael E. Porter, Mark R. Kramer and David Lane
Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India
Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised October 2017.)
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
Until the close of the last decade, health consumers received much of their knowledge and advice about prescription drugs from their physicians or other health care professionals. Today, pharmaceutical companies are spending several... View Details
Keywords: by Manda Salls
- 01 Dec 1996
- News
New Releases
a competitive factor. In a three-year study of pharmaceutical and biotechnology firms, Pisano shows that the development of distinctive and superior process technologies can lower costs, improve quality, and... View Details
- January 1991 (Revised August 1992)
- Case
Race to Develop Human Insulin
Describes the race to develop human insulin. View Details
Brandenburger, Adam M., Vijay Krishna, and Paul Barese. "Race to Develop Human Insulin." Harvard Business School Case 191-121, January 1991. (Revised August 1992.)
- May 2023
- Case
Legacy Partners
By: Royce Yudkoff and Richard S. Ruback
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021. The company, based in Sacramento CA, was a compounding pharmacy serving Total Parenteral Nutrition ("TPN") patients nationwide.... View Details
Keywords: Acquisition; Growth and Development Strategy; Competitive Strategy; Business or Company Management; Pharmaceutical Industry
Yudkoff, Royce, and Richard S. Ruback. "Legacy Partners." Harvard Business School Case 223-092, May 2023.
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
pharmaceutical firm B creates a drug that treats the same ailment and prepares to bring the drug to market. According to best estimates, this new competition will reduce the price of A's product to $2.55 per... View Details
Keywords: by Max H. Bazerman
- February 2024
- Teaching Note
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul
Teaching Note for HBS Case No. 724-412. View Details
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
head of the European Commission's competition authority, was widely believed to be looking for an opportunity to assert Continental independence. It seems the real reason Welch was surprised is that he just didn't pay enough attention.... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 19 Sep 2017
- First Look
First Look at New Research and Ideas, September 19
pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO Martin Shkreli, had recently brought media attention to this issue. Baum believed it would be relatively easy for Imprimis to... View Details
Keywords: Sean Silverthorne
- February 2000 (Revised June 2003)
- Case
Pepcid AC: Racing to the OTC Market
By: Charles King III, Alvin J. Silk, Ernst R. Berndt and Lisa R. Klein
Pepcid management must decide whether to risk all in a race to be first in the over-the-counter market with a new heartburn remedy. View Details
Keywords: Competitive Advantage; Product Positioning; Markets; Research; Marketing Strategy; Product Development; Decision Choices and Conditions; Pharmaceutical Industry
King, Charles, III, Alvin J. Silk, Ernst R. Berndt, and Lisa R. Klein. "Pepcid AC: Racing to the OTC Market." Harvard Business School Case 500-073, February 2000. (Revised June 2003.)
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- 15 Sep 2009
- First Look
First Look: September 15
Abstract We study competitive interaction between two alternative models of digital content distribution over the Internet: peer-to-peer (p2p) file sharing and centralized client-server distribution. We present microfoundations for a... View Details
Keywords: Martha Lagace
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- 01 Dec 2003
- News
The Next Big Thing
It's a case of competition and strategy on a global scale, and the stakes could hardly be higher. The prize? Leadership in the realm of life sciences, a field that experts say will shape and dominate 21st-century enterprise. What city or... View Details
- September 2010
- Teaching Note
Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)
By: Willy C. Shih
Teaching Note for 611009. View Details
- 28 Aug 2017
- Research & Ideas
Should Industry Competitors Cooperate More to Solve World Problems?
Source: Cecilie_Arcurs George Serafeim has a startling suggestion to fix the world’s biggest environmental, social, and governance (ESG) problems such as water pollution, deforestation, and wealth inequality: encourage companies within industries to do less competing... View Details